Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Clearmind Medicine Inc., a clinical-stage biopharmaceutical company listed on Nasdaq, announced the publication of three U.S. patent applications for novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines, including PEA. These patents potentially cover therapeutic uses for depression, PTSD, pain, and substance use disorders, exp…
3 E Network Technology Group Limited announces that its Nordic subsidiary, Aurora Core Technology Oy, has entered the implementation phase for a multi-megawatt green energy AI data center project in Finland. The subsidiary is managing procurement, grid interconnection, environmental approvals, municipal waste heat monetization negotiations, local e…
SK hynix looks positioned to extend recent improvement as DRAM and NAND chips reflate on AI and server demand. This is a tactical long trade sized for a mid-term swing: entry at $95.00, a stop at $82.50, and a target at $120.00. The trade leans on clearer demand signals, expanding high-margin HBM exposure, and an overall memory cycle recovery while…
BridgeBio Pharma announced results from a peer-reviewed real-world study demonstrating that Acoramidis significantly reduces the risk of clinical worsening events in transthyretin amyloid cardiomyopathy (ATTR-CM) patients compared to Tafamidis. The study showed a 34% reduction in composite risk of worsening, including heart failure hospitalization …
Archer (ACHR) trades at $5.695 after a 62% drop from its 52-week high. Negative profitability, steep cash burn, and heavy short activity combine with uncertain certification and integration milestones to create a high-risk setup. We favor a tactical short over the next 45 trading days, with a clear entry, stop and target.
VEON Ltd., a global digital operator listed on NASDAQ, announced an increased share buyback program worth approximately $200 million to repurchase 3.9% of its outstanding shares. The company plans to cancel all repurchased shares, reinforcing its capital allocation discipline and commitment to long-term value creation. This program represents a sig…
Winnebago Industries announced it will release its fourth quarter and full fiscal 2026 financial results on October 21, 2026, before the NYSE opens. A conference call will follow, hosted by its CEO and CFO, accessible via the company's investor relations website. The company is a leading North American manufacturer of outdoor recreation products in…
Artelo Biosciences announced the filing of a new provisional patent application for ART27.13, a dual cannabinoid receptor agonist, targeting obesity treatment both as monotherapy and combined with GLP-1 receptor agonists like semaglutide. Nonclinical studies demonstrated up to 40% weight loss in obese mice when ART27.13 was combined with semaglutid…
Turning Point Brands (TPB) has been punished this year on FDA-related headlines and heavy marketing investments that temporarily compress earnings. The sell-off has pushed technicals into deeply oversold territory while balance-sheet metrics and cash flow remain intact. We upgrade TPB to a buy for a tactical swing trade - the market is now overly c…
Beneficient has announced a comprehensive strategy to eliminate the fraudulent HCLP debt of approximately $130 million and convert the former CEO Brad Heppner's substantial equity interests valued around $850 million into common stock, while terminating all related agreements. This follows Heppner's conviction for securities and wire fraud. The res…
Wave Life Sciences initiated a Phase 2a clinical trial evaluating its investigational RNA medicine WVE-007 in combination with tirzepatide for obesity treatment. Preclinical and emerging data indicate that WVE-007, utilizing GalNAc-siRNA technology, induces fat loss without muscle loss and could enhance weight loss beyond GLP-1 therapies alone. The…
TON Strategy Company is a leveraged, asymmetric play on the revival and market adoption of GRAM. For traders willing to accept high volatility and structural uncertainty, a modest long position around $1.20 with a tight stop and a $2.80 target offers a favorable risk-reward if token catalysts materialize over the next 45 trading days.
Nexentis Technologies Inc., through its wholly-owned subsidiary MitoCareX Bio Ltd., is evaluating additional commercially available approaches to obtain proteins for its in-vitro drug discovery research. This initiative aims to broaden research capabilities, increase flexibility, and support future discovery programs. The evaluation is in early sta…
Sprouts Farmers Market is trading roughly 41% below my fair value estimate of $118. The stock's recent pullback has pushed technicals into oversold territory while fundamentals - solid gross margins, positive new-store vintages and manageable valuation versus future earnings - argue for a rebound. This is a long trade idea with entry $69.50, stop $…
Biomea Fusion, a clinical-stage company focused on diabetes and obesity treatments, has terminated its proposed public offering of securities due to current market conditions deemed unfavorable for stockholders. No shares were sold, and the decision reflects management's commitment to protecting shareholder interests amid volatile markets.
DRDGOLD (DRD) is a niche surface-gold retreatment specialist trading at a modest multiple with a $2.31B market cap and 9.1x PE. With dividend income, improving technicals and rising short interest, the stock offers an asymmetric risk-reward for a long trade over the next 180 trading days as the company moves toward higher production in fiscal 2027.
Lexeo Therapeutics, a clinical stage biotech company focused on genetic diseases, announced its participation in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum scheduled for September 30, 2026. The event will be webcast live and later available for replay on the company's website.
AC Immune SA reported positive safety and immunogenicity data through week 100 in Part 1 of its VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson's disease patients. All primary endpoints—safety, tolerability, and immunogenicity—were met, with 100% of patients developing antibodies against the target. The trial showed strong antibody penetr…
Roivant announced that Immunovant's proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve statistical significance on its primary efficacy endpoint. Despite positive trends on secondary measures and a favorable safety profile, development for this indication will cease. Immunovant remains focused on advancing …
Oruka Therapeutics announced positive Week 28 data from the EVERLAST-A Phase 2a trial evaluating ORKA-001 in moderate-to-severe plaque psoriasis. Results show increasing skin clearance rates (PASI 100 up to 71.4%) months after the last dose at Week 4, with a strong safety and tolerability profile consistent with the IL-23p19 monoclonal antibody cla…
Avalo Therapeutics announced its participation in the upcoming European Academy of Dermatology and Venereology (EADV) 2026 Congress with a late-breaker oral presentation and poster showcasing the efficacy and safety data from its Phase 2 placebo-controlled LOTUS trial of abdakibart in treating moderate to severe hidradenitis suppurativa. The data p…
GXO Logistics has begun pilot deployments of a new Labor Management System (LMS) across major regions including North America and Europe. The LMS aims to standardize labor management globally, enhance workforce planning, improve operational efficiencies, and support the company's growth and profitability goals. Full-scale rollout is planned for 202…
Seer, Inc., a US-listed proteomics company, announced that Nanyang Technological University researchers will present early findings from the PRECISE-SG100K study at the 2026 HUPO World Congress. The study leverages Seer's Proteograph Product Suite combined with advanced mass spectrometry to deeply analyze the circulating proteome of 10,000 particip…
Immunovant announced topline results from its proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus (CLE). The study did not achieve statistical significance on the primary endpoint at 12 weeks. Despite positive trends in some secondary endpoints and a favorable safety profile, the company will discontinue development of IMVT…
Auddia Inc. announces the appointment of former U.S. Secretary of Defense Mark T. Esper to the board of LT350, a subsidiary of the pending merger that would form McCarthy Finney Inc. Esper's expertise enhances LT350’s positioning as a national security-aligned AI-edge computing company targeting commercial and defense markets. The merger, if comple…
